Business
SOPHiA GENETICS to Highlight Innovations and Announcements at Investor Day on September 20, 2022
BOSTON and GENEVA, Switzerland, Sept. 20, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space,
About this update from Sophia Genetics Sa
[{"type":"text","content":"BOSTON and GENEVA, Switzerland, Sept. 20, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, will host its first-ever Investor Day TODAY in-person at PUBLIC Hotel in New York City. The event will begin at 1:30 p.m. EDT and is expected to conclude at approximately 5:30 p.m. EDT. Presenters include: Troy Cox, Chairman of the boardDr. Jurgi Camblong, Chief Executive Officer and co-founderKen Freedman, Chief Revenue OfficerPeter Casasanto, Chief BioPharma OfficerDr. Philippe Menu, Chief Medical OfficerAbhi Verma, Chief Technology OfficerDr. Zhenyu Xu, Chief Scientific OfficerRoss Muken, Chief Financial Officer Today’s Investor Day will offer an opportunity for investors to learn from the company’s executive team about its key differentiators and strategies that will help drive SOPHiA Genetics’ long-term growth. Due to limited capacity, advanced registration is required for in-person attendance. For more information, interested parties may contact Investor Relations at [email protected]. Additionally, the event will be webcast live and all interested parties are invited to access the webcast from the Investor Relations section of the company’s website. About SOPHiA GENETICSSOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and Instagram. Where others see data, we see answers SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the ap...